Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ (Israel) Cerebral Protection Device During TAVR

Late breaking trials at the ACC include the data from the first randomized, multi-center DEFLECT III clinical trial, testing the TriGuard Cerebral Detection Device designed to protect the brain during cardiovascular procedures: Use of the TriGuard was safe with numerically better in-hospital…










